» Articles » PMID: 29881288

High SRPX2 Protein Expression Predicts Unfavorable Clinical Outcome in Patients with Prostate Cancer

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2018 Jun 9
PMID 29881288
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sushi repeat-containing protein X-linked 2 (SRPX2) is overexpressed in a variety of different tumor tissues and correlated with poor prognosis in patients. Little research focuses on the role of SRPX2 expression in prostate cancer (PCa), and the clinicopathological significance of the protein expression in this tumor is relatively unknown. However, our previous transcriptome data from those cancer stem-like cells indicated the role of SRPX2 in PCa.

Materials And Methods: In this study, RT-PCR and Western blotting were firstly used to examine the SRPX2 expression in three PCa cell lines including LNCaP, DU145, and PC3, and then SRPX2 protein expression was immunohistochemically investigated and statistically analyzed in a series of 106 paraffin-embedded PCa tissue specimens.

Results: Significantly lower levels of SRPX2 expression were verified in the LNCaP cells, compared with the expression in the aggressive DU145 and PC3 cells, in both mRNA and protein levels. Immunohistochemically, there were variable SRPX2 protein expressions in the clinical samples. Moreover, high levels of SRPX2 expression in the PCa tissues were significantly associated with Gleason score (=0.008), lymph node metastasis (=0.009), and distant metastasis (=0.021). Furthermore, higher levels of SRPX2 expression in the PCa tissues were significantly associated with shorter overall survival (OS) (<0.001).

Conclusion: Our results demonstrate that SRPX2 is highly expressed in aggressive PCa cells in vitro, and its protein expression in PCa is significantly associated with malignant clinical features and shorter OS, strongly indicating its prognostic value in prostate cancers.

Citing Articles

The oncogenic role of LGR6 overexpression induced by aberrant Wnt/β-catenin signaling in lung cancer.

Sunaga N, Kaira K, Shimizu K, Tanaka I, Miura Y, Nakazawa S Thorac Cancer. 2023; 15(2):131-141.

PMID: 38014454 PMC: 10788478. DOI: 10.1111/1759-7714.15169.


Substance P is overexpressed in cervical squamous cell carcinoma and promoted proliferation and invasion of cervical cancer cells <em>in vitro</em>.

Wang Y, Yuan S, Ma J, Liu H, Huang L, Zhang F Eur J Histochem. 2023; 67(3).

PMID: 37522867 PMC: 10476533. DOI: 10.4081/ejh.2023.3746.


SRPX2 promotes cancer cell proliferation and migration of papillary thyroid cancer.

Guo H, Liu R, Wu J, Li S, Yao W, Xu J Clin Exp Med. 2023; 23(8):4825-4834.

PMID: 37306872 PMC: 10725347. DOI: 10.1007/s10238-023-01113-1.


Global hypo-methylation in a proportion of glioblastoma enriched for an astrocytic signature is associated with increased invasion and altered immune landscape.

Boot J, Rosser G, Kancheva D, Vinel C, Lim Y, Pomella N Elife. 2022; 11.

PMID: 36412091 PMC: 9681209. DOI: 10.7554/eLife.77335.


SRPX2 Promotes Tumor Proliferation and Migration via the FAK Pathway in Papillary Thyroid Carcinoma.

Luo N, Tan Y, Deng H, Wu W, Mei L, Huang X J Oncol. 2022; 2022:5821545.

PMID: 36385962 PMC: 9649326. DOI: 10.1155/2022/5821545.


References
1.
Tang H, Zhao J, Zhang L, Zhao J, Zhuang Y, Liang P . SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells. Cell Mol Neurobiol. 2015; 36(7):1067-76. PMC: 11482440. DOI: 10.1007/s10571-015-0300-9. View

2.
Royer B, Soares D, Barlow P, Bontrop R, Roll P, Robaglia-Schlupp A . Molecular evolution of the human SRPX2 gene that causes brain disorders of the Rolandic and Sylvian speech areas. BMC Genet. 2007; 8:72. PMC: 2151080. DOI: 10.1186/1471-2156-8-72. View

3.
Schwanzer-Pfeiffer D, Rossmanith E, Schildberger A, Falkenhagen D . Characterization of SVEP1, KIAA, and SRPX2 in an in vitro cell culture model of endotoxemia. Cell Immunol. 2010; 263(1):65-70. DOI: 10.1016/j.cellimm.2010.02.017. View

4.
Royer-Zemmour B, Ponsole-Lenfant M, Gara H, Roll P, Leveque C, Massacrier A . Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. Hum Mol Genet. 2008; 17(23):3617-30. DOI: 10.1093/hmg/ddn256. View

5.
Wilson R, Norris E, Brachvogel B, Angelucci C, Zivkovic S, Gordon L . Changes in the chondrocyte and extracellular matrix proteome during post-natal mouse cartilage development. Mol Cell Proteomics. 2011; 11(1):M111.014159. PMC: 3270109. DOI: 10.1074/mcp.M111.014159. View